<DOC>
	<DOCNO>NCT01021423</DOCNO>
	<brief_summary>A study evaluate efficacy lenalidomide maintenance therapy completion first-line combination chemotherapy patient mantle cell lymphoma ( MCL ) candidate transplantation achieve partial response ( PR ) complete response ( CR ) . This study prematurely terminate sponsor light new unpublished data render current design study longer clinically relevant . A study design control arm active treatment longer appropriate . The termination trial base safety concern study .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Lenalidomide Maintenance Therapy After Completion First-line Combination Chemotherapy Patients With Mantle Cell Lymphoma ( MCL ) .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Histologicallyproven mantle cell nonHodgkin 's lymphoma , One follow firstline induction chemotherapy regimens rituximab : ( 1 ) combination regimen contain follow component : cyclophosphamide , vincristine , adriamycin glucocorticoid ; ( 2 ) Fludarabine contain regimen FC ( fludarabine , cyclophosphamide ) Achieved PR good response firstline induction chemotherapy regimen ( assessed 2007 Revised Response Criteria Malignant Lymphoma ) ECOG performance status score â‰¤ 2 Willing follow pregnancy precaution Patients receive 1 line induction chemotherapy ; Patients receive less 4 cycle RCHOP , RCHOPlike , RFC ineligible ; Patients achieve stable disease progressive disease best response first lineinduction chemotherapy ; Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5*10^9/L ) Platelet count &lt; 60,000/mm^3 ( 60*10^9/L ) Serum aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ) &gt; 3.0 time upper limit normal ( ULN ) , except patient document liver involvement lymphoma Serum bilirubin &gt; 1.5 time ULN , except case Gilbert 's Syndrome document liver involvement lymphoma Calculated creatinine clearance ( i.e . CockcroftGault formula ) &lt; 30 mL /min Active history central nervous system ( CNS ) lymphoma leptomeningeal involvement lymphoma Subjects high risk deep vein thrombosis ( DVT ) willing take DVT prophylaxis Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>CC-5013</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>